AstraZeneca Stock Hits New 52-Week High (AZN)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- AstraZeneca (NYSE: AZN) hit a new 52-week high Monday as it is currently trading at $52.13, above its previous 52-week high of $51.94 with 841,931 shares traded as of 1 p.m. ET. Average volume has been 2.2 million shares over the past 30 days.

AstraZeneca has a market cap of $63.74 billion and is part of the health care sector and drugs industry. Shares are up 9.1% year to date as of the close of trading on Friday.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. The company has a P/E ratio of 10.2, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full AstraZeneca Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting

AstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results